Famotidine tablets 20 mg №20


Manufacturer: Ukraine

Benign stomach ulcer. Peptic ulcer of the duodenum (treatment and prevention of relapses). Hypersecretory conditions such as Zollinger-Ellison syndrome. Treatment of gastroesophageal reflux disease (reflux-esophagitis). To prevent the development of symptoms and erosions or ulceration associated with gastroesophageal reflux disease.



Famotidine 20 mg Composition
active substance: famotidine;

1 tablet contains 20 mg famotidine;

excipients: lactose monohydrate, microcrystalline cellulose, crospovidone, colloidal anhydrous silicon dioxide, talc, stearic acid, sepifilm 752 white.

Famotidine 20 mg Dosage form.

Film-coated tablets.

Basic physical and chemical properties: coated tablets, white, round, with a biconvex surface.

Pharmacotherapeutic group. Drugs for the treatment of peptic ulcers and gastroesophageal reflux disease. H2 receptor antagonists. ATX code A02B A03.

Famotidine 20 mg Pharmacological properties


Famotidine is a blocker of H2-histamine receptors in the stomach wall, therefore it reduces the secretion of gastric juice. Under the action of the drug, both the concentration and the amount of gastric juice decrease, and, accordingly, the amount of pepsin. The action of 20 mg and 40 mg of famotidine lasts for 10-12 hours. A single evening dose (20 mg or 40 mg) reduces basal and nocturnal gastric secretion. The blocking rate of gastric acid secretion at night is 86-94% and lasts at least 10 hours.

When the same dose is taken in the morning, the degree of blocking of gastric acid secretion by food stimulated within 3-5 hours is 76-84%, and after 8-10 hours – 25-30%.

Famotidine practically does not affect either the “hungry” level of gastrin, or its level after a meal.

Famotidine does not affect either gastric emptying, or the secretory function of the pancreas, or hepatic circulation and portal blood flow. Famotidine does not affect the cytochrome P450 enzyme system of the liver. Famotidine does not affect serum hormone levels. Has no antiandrogenic effect.


Absorption. Famotidine is absorbed quickly and completely. Bioavailability is 40-45%, regardless of the contents of the stomach.

Distribution in the body: after oral administration, the maximum concentration of famotidine in the blood plasma is observed after 1-3 hours. Repeated doses do not lead to drug accumulation. The connection with plasma proteins is insignificant – 15-20%.

The plasma half-life is 2.3-3.5 hours. In the presence of severe renal failure, the elimination half-life may increase to 20 hours.

Metabolism: metabolized in the liver, the only known metabolite is sulfoxide.

Excretion: the renal clearance of the drug is 250-450 ml per minute, which indicates tubular excretion. 25-30% of the dose taken orally is excreted in the urine unchanged. Only a small amount of famotidine is excreted as sulfoxide.

The pharmacokinetic parameters of the drug in the body of a healthy elderly person and a child do not differ significantly from the pharmacokinetic parameters in an adult.

Clinical characteristics.

Benign stomach ulcer.

Duodenal ulcer (treatment and prevention of relapse).

Hypersecretory conditions such as Zollinger-Ellison syndrome.

Treatment of gastroesophageal reflux disease (reflux esophagitis).

Prevention of the development of symptoms and erosion or ulceration associated with gastroesophageal reflux disease.

Hypersensitivity to the active substance, other antagonists of H2-histamine receptors or other components of the drug.

Childhood, pregnancy and lactation (due to lack of necessary clinical experience).